GlassScriptPhysician profile
John D Pappas
NPI 1033110234
$26,371.31
in general payments reported to CMS, 2019-2025
25 companies · $1,342 in 2025
The $1,342 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,888 · 2020: $1,870 · 2021: $4,033 · 2022: $5,183 · 2023: $2,584 · 2024: $5,472 · 2025: $1,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,204 · Travel and Lodging: $3,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,203.90 |
| Travel and Lodging | $3,194.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $8,746.90 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Valiant Captivia |
| Medtronic Vascular, INC. | $5,419.16 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $2,948.79 | 2019-2021 | |
| Abiomed | $2,881.75 | 2019-2025 | Impella |
| Penumbra, INC. | $2,212.36 | 2024 | Indigo System |
| Edwards Lifesciences Corporation | $1,384.31 | 2019-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $669.20 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $365.76 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $335.42 | 2021-2023 | Verquvo |
| Abbott Laboratories | $270.21 | 2022-2025 | Cardiomems, Navitor, Mitraclip |
| Biotronik INC. | $261.78 | 2021-2022 | |
| Angiodynamics, INC. | $156.15 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $151.22 | 2019-2025 | Lifevest |
| Cook Medical LLC | $112.62 | 2023 | Zilver Ptx |
| Esperion Therapeutics, INC. | $76.64 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $76.25 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $74.95 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.45 | 2022-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $46.35 | 2023-2024 | |
| Cardiovascular Systems INC. | $33.71 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $26.22 | 2023 | Inpefa |
| Amarin Pharma, INC. | $22.67 | 2020 | |
| Boston Scientific Corporation | $21.78 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.83 | 2023 | Camzyos |
| Kiniksa Pharmaceuticals, LTD. | $12.83 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pappas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.